Author

H. Goldschmidt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Dervan· 1 shared A. Pratapa· 1 shared A. Ratushny· 1 shared A. Sedlmeier· 1 shared A. Thakurta· 1 shared A. Trumpp· 1 shared B. A. Walker· 1 shared B. Brors· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Dervan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 27, 2023

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

R. Lutz, F. Gruenschlaeger, M. Simon…·S. Haas

This study examines immune changes in multiple myeloma survivors years after treatment, finding sustained immune alterations linked to residual disease and therapy.

DOI 10.1101/2023.05.27.542555

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivAug 22, 2019

Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 As Marker of Aggressive Disease

M. J. Mason, C. Schinke, C. Eng…·J. A. Guinney

The paper identifies PHF19 as a marker of aggressive multiple myeloma and shows a simple four-feature model performs as well as complex gene expression models.

DOI 10.1038/s41375-020-0742-z

humanbulk RNA-seq

𝕏 PostBluesky